Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

30 Sept 2015

Abstract excerpt

The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for HER2 (ERBB2, neu) positive breast cancer patients. Today, patients eligible for trastuzumab are selected using HER2 expression/amplification status of the primary tumor. However, acquired and inherent resistance to anti-HER2 therapy in these patients poses a significant challenge, and better patient stratification...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Treatment and Pharmacology
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26452383
DOI: 10.2174/156800961508151001101742

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerPMID 26452383Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

“Omics” of HER2-Positive Breast CancerSemantic proximity Read ↗

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read ↗

Analysis of different HER-2 mutations in breast cancer progression and drug resistance.Semantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.